Table 2 Adverse events reported in relation to plerixafor treatment

From: Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

  Myeloma Lymphoma All cases
Patients in group, N (%) 32 (57) 24 (43) 56 (100)
Any toxicity 13 (41) 6 (25) 19 (34)
Diarrhea and frequent bowel movements 9 (28) 2 (8) 11 (20)
Flatulence and gut discomfort 5 (16) 3 (12) 8 (14)
Injection site reactions 8 (25) 2 (8) 10 (18)
Bone pain 2 (6) 2 (4)
Hot flushing 1 (3) 1 (4) 2 (4)
Others 5 (16) 4 (17) 9 (16)